198821-22-6
198821-22-6 structure
- Name: merimepodib
- Chemical Name: [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
- CAS Number: 198821-22-6
- Molecular Formula: C23H24N4O6
- Molecular Weight: 452.460
- Catalog: Signaling Pathways Anti-infection HBV
- Create Date: 2018-09-20 14:53:48
- Modify Date: 2024-01-02 19:29:16
-
Merimepodib is a novel noncompetitive inhibitor of IMPDH (Inosine monophosphate dehydrogenase).
| Name | [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate |
|---|---|
| Synonyms |
MMPD
Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester (3S)-Tetrahydro-3-furanyl [3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)benzyl]carbamate Tyverb/Tykerb Merimebodib VX-497 merimepodib Merimepodib (USAN/INN) (3S)-tetrahydrofuran-3-yl [3-({[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoyl}amino)benzyl]carbamate |
| Description | Merimepodib is a novel noncompetitive inhibitor of IMPDH (Inosine monophosphate dehydrogenase). |
|---|---|
| Related Catalog | |
| In Vitro | VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal[1]. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC50s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC50 of 380 nM and a corresponding CC50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine[2]. |
| In Vivo | Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation[1]. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals[3]. |
| Cell Assay | The murine fibroblast L929 cell line is cultured in Eagle minimal essential medium supplemented with 10% fetal bovine serum, nonessential amino acids, 50 U of penicillin per mL, 50 μg of streptomycin per mL, and 2 mM l-glutamine. EMCV is infected at 500 PFU/107 L929 cells. Cells are left untreated or are treated with different concentrations of murine IFN-α alone, VX-497 alone, or combinations thereof. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 571.4±50.0 °C at 760 mmHg |
| Molecular Formula | C23H24N4O6 |
| Molecular Weight | 452.460 |
| Flash Point | 299.4±30.1 °C |
| Exact Mass | 452.169586 |
| PSA | 130.93000 |
| LogP | 2.05 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.632 |
| Storage condition | 2-8℃ |